Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Rating of “Reduce” by Analysts

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has been given a consensus rating of “Reduce” by the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $15.00.

Several brokerages recently weighed in on IART. Wall Street Zen upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. upped their price objective on shares of Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a research note on Friday, October 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Truist Financial restated a “hold” rating and set a $13.00 price target (down previously from $15.00) on shares of Integra LifeSciences in a report on Monday, November 3rd. Finally, Citigroup lowered their price target on Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating for the company in a research report on Friday, October 31st.

Integra LifeSciences Trading Down 2.0%

NASDAQ IART opened at $13.58 on Friday. The company has a quick ratio of 1.80, a current ratio of 3.14 and a debt-to-equity ratio of 1.73. The stock’s 50-day simple moving average is $12.62 and its two-hundred day simple moving average is $13.44. Integra LifeSciences has a twelve month low of $10.87 and a twelve month high of $27.13. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -2.10 and a beta of 1.02.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Thursday, October 30th. The life sciences company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.11. The company had revenue of $402.06 million during the quarter, compared to the consensus estimate of $414.31 million. Integra LifeSciences had a positive return on equity of 14.06% and a negative net margin of 30.15%.Integra LifeSciences’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.41 EPS. Integra LifeSciences has set its Q4 2025 guidance at 0.790-0.840 EPS and its FY 2025 guidance at 2.190-2.240 EPS. Research analysts forecast that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Jeffrey A. Graves purchased 9,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 5th. The shares were acquired at an average price of $11.35 per share, for a total transaction of $102,150.00. Following the completion of the acquisition, the director directly owned 41,086 shares in the company, valued at approximately $466,326.10. The trade was a 28.05% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.54% of the stock is owned by insiders.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Integra LifeSciences by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after buying an additional 1,975 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Integra LifeSciences during the first quarter valued at approximately $277,000. Goldman Sachs Group Inc. grew its stake in Integra LifeSciences by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock worth $36,515,000 after purchasing an additional 35,790 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Integra LifeSciences by 23.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after purchasing an additional 45,693 shares in the last quarter. Finally, Strs Ohio purchased a new position in Integra LifeSciences during the first quarter valued at $400,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.